Lung Cancer
Disease Group
Lung Cancer
Disease Group Profile
The thoracic malignancy disease group was established in 2021 to direct the lung cancer and mesothelioma research activities of ACCRU. It is led by Dr. Stephen Liu, the Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, Dr. Aaron Mansfield, Professor of Oncology at Mayo Clinic Cancer Center, and Dr. Bryan Faller, Medical Director of Cancer Research at Missouri Baptist Medical Center in St. Louis, MO.
Disease Group Leaders
Bryan Faller, M.D.
Heartland NCI Community Oncology Research Program
Bryan Faller, M.D. a community medical oncologist based in St. Louis, Missouri, is the Alan P. Lyss Endowed Chair in Cancer Research at Missouri Baptist Medical Center and the PI of Heartland Cancer Research NCI Community Oncology Research Program (NCORP). He has served on the ACCRU Scientific and Administrative Review Committee since 2013 and on the ACCRU Board of Directors since 2018.
Stephen Liu, M.D.
MedStar Georgetown University Hospital
Stephen Liu, M.D. is the Director of Thoracic Oncology and Head of Developmental Therapeutics at Georgetown University Lombardi Comprehensive Cancer Center. He is a medical oncologist focused on the treatment of lung cancer with extensive experience in immunotherapy, targeted therapy, and rational clinical trial design.
Aaron Mansfield, M.D.
Mayo Clinic Rochester
Aaron Mansfield, M.D. is a medical oncologist with expertise in the treatment of thoracic malignancies. His efforts have supported FDA-approval of multiple novel therapeutics for lung cancers, mesothelioma, and thyroid malignancies. His NIH, DoD and Mark Foundation funding have supported the development of novel biomarkers.
Disease Group Clinical Trials
A7471042
Archer 1042: A Phase 2 Study Of Dacomitinib In Advanced Non-small Cell Lung Cancer (Post-chemotherapy Or Select First Line Patients) To Evaluate Prophylactic Intervention On Dermatologic And Gastrointestinal Adverse Events And Patient Reported Outcomes
RC0524
A Randomized Phase II Study of ALIMTA? (Pemetrexed) and GEMZAR? (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer
RC0527
A Randomized Phase II Study of ALIMTA? (Pemetrexed) and GEMZAR? (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer
RC1126
A Randomized Phase II Trial of Erlotinib Alone or In Combination with Bevacizumab in Patients with Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations